Nefritis Lupica
DOI:
https://doi.org/10.31053/1853.0605.v65.n3.23565Palabras clave:
Nefritis Lupica, lupus eritematoso sistémico, LESResumen
El Lupus eritematoso sistémico (LES) es una enfermedad autoinmune, multisistémica que se caracteriza por numerosos patrones de manifestaciones clínicas e inmunológicas. Uno de los marcadores distintivos es la producción de autoanticuerpos, especialmente a antígenos nucleares que incluyen DNA doble cadena ( ds-DNA), histonas y ribonucleoproteínas solubles (RNP) y antígeno Sm. Numerosos factores contribuyen a la formación de los mismos y éstos incluyen: la pérdida de la tolerancia de las células B y T, un aumento de la concentración y una presentación anormal de autoantígenos (e.g. nucleosomas), y defectos en el clereance de células apoptóticas entre otros. La variabilidad en estos eventos influencian la naturaleza y el compromiso orgánico en el LES.
Descargas
Referencias
Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005 14, 19-24. [Abstract]
Walker WG, Solez K. Renal involvement in disorders of connective tissue. IN: Earley LE, Gottschalk CW, (eds). Diseases of Kidneys. ( vol.2) Little, Brown: Boston,1979,pp1259-1288.
Stahl –Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of Systemic lupus erythematosus in southern Sween: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685-91.
Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern chinese population. Rheumatology 2000; 39:399-406.[Full Text]
Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine ( Baltimore) 1999;78:167-75. [Abstract]
Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10: 413-24.[Full Text]
Fiehn C, Hajjar Y, Nueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade : importance of early diagnosis and treatment. Ann Rheum Dis 2003 ; 62: 435-39. [PubMed Central Open-Access]
Ward MM. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. Am J Kidney Dis 2000;36:516-525. [Abstract]
Datta SK, Kaliyapemural A: Nucleosome-driven autoimmune response in lupus. Pathogenic T Helper cell epitopes and costimulatory signals. Ann N Y Acad Sci 815: 155-170, 1997.
Mohan C, Adams S, Stanik V, Datta SK: Nucleosomae: A major immunogen for pathogenic autoantibody –inducing helper T cells from lupus mice: Possible selection by cationic autoantigens. Proc Nat Acad Sci U S A 88: 11271-75,1991.
Desai-Metha A, Mao C, Rajagopalan S, Robinson T, Datta SK: Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 95: 531-541, 1995. [PubMed Central Open-Access]
Herrmann M, Voll RE, Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21: 424-426, 2000.[Abstract]
Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1083-1086, 1994.[Full text]
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241-1250,1998.[Full Text]
Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrman M: Impaired uptake of apoptotic cells into tangible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46:191-201,2002. [Full Text]
Bruns a, Blass S, Hausdorf G, Burmester GR, Hiepe F: Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis & Rheum 43: 2307-2315,2000. [Full Text]
Kramers C, Hylkema MN, et al. Antinucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94: 568-577,1994 [Full text]
Van Bruggen MC, Kramers C, et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 12:57-66, 1997.[Full text]
Klippel JH. How to alter the course of lupus nephritis. J Musculoskeletal Dis 1988; 5:29-43.
Wallace DJ, Podell TE, Weiner JM, et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72:209-220. [Abstract]
Wallace DJ, Hahn BH. Dubois´ Lupus Erythematosus. 6 th. Ed. 2002.
Churg J, Sobin LH: Renal disease: Classification and Atlas of Glomerular Disease, Tokio, Igaku-Shoin,1982. [Full Text]
Churg J, Bernstein J, Glassock RJ: Renal Disease: Classification and Atlas of Glomerular Diseases, 2nd Ed., New York, Igakyshoin, 1995.
Weening JJ, Dagati VD, Schwartz MM et al. The Classification of Glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241-250, 2004.[Full Text]
Austin HA, Muenz LR, Joyce KM, Antonovych TT, et al. Diffuse proliferative
lupus nephritis: identification of specific pathologic features affecting renal
outcome. Kidney Int 1984;25: 135-148. [Abstract]
26. Moroni G, Pasquali S, Quaglini S et al. Clinical and prognostic value of serial
renal biopsies in lupus nephritis. Am J kidney Dis 1999 ,34 530-39.[Abstract]
Esdaile JM, Federgreen W, Quintal H et al. Predictors of one year outcome in lupus nephritis. The importance of renal biopsy. Q J Med 1991; 81: 907-18. [Abstract]
Contreras G, pardo V, Cely C, Borja E et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14: 890-95. [Abstract]
Schwartz MM, Lan SP, Bernstein J et al. Role of the pathology indices in the management of severe glomerulonephritis. LN Collaborative Study Group. Kidnery Int 1992; 42: 743-48.
Eslaide JM, Abrahamowicz M, MacKenzie T, et al. The time dependence of long term prediction in lupus nephritis. Arthritis Rheum 1994;37:359-68.[Abstract]
Houssiau FA. Mamagement of Lupus Nephritis: AN Update. J Am Soc Nephrol 15: 2694-2704,2004.[Abstract]
Austin HA, Klippel JH, Balow et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J med 314: 614-619,1986. [Abstract]
Boumpas DT, Austin HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992. [Abstract]
Illei GG, Austin HA, Crane N, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern med 135:248-257,2001.[Full Text]
Houssiau FA, D´Cruz DP, Haga HJ, Hughes GR: Short course of weekly low dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis. A oreliminary study. Lupus 1:31-35,1991. [Abstract]
D´Cruz D, Cuadrado MJ, Mujic F, et al. Inmmunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275-282,1997.
Houssiau FA, Vasconcelos C, D ´Cruz D, et al. IMMunosuppressive therapy in lupus nephritis : The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus hig-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131,2002.[Full text]
Houssiau FA, Vasconcelos C, D´Cruz d, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long term follow up of patients in the Euro Lupus Nephritis Trial. Arhtritis & Rheum 50: 3934-40,2004.[Full Text]
Mok CC, Ying KC et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide . Am J Med 119:355, 2006.[Abstract]
Adu D. Treatment of proliferative lupus nephritis: a changing landscape. Kidney Int 70: 616-8. [Abstract]
Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis : A meta-analysis of randomized controlled trials. Am J kidney dis 43. 197-208,2004.[Abstract]
Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14; 58-63,1999.[Full text]
Lui SL, Chan LY, Zhang XH et al. Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischemia reperfusiuon injury. Nephrol Dial Transplant16. 1577-1582,2001.[Full Text]
Chan TM; Wong WS, Lau CS et al. Prolonged follow up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednsiolone and mycophenolate mofetil. J Am Soc Nephrol 12,2001.
Hu W, Liu Z, chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 115:705-709,2002.[Full Text]
Appel G, Ginzler EM et al. Multicenter controlled trial of mycophenolate mofetil as induction therapy for severe lupus nephritis . J Am Soc Nephrol 14; 2003.
Ginzler EM, Dooley MA, aranow C et al. Mycophenolate mofetil or intavenous cyclophosphamide induction therapy in lupus nephritis. N Engl J Med 2005; 353:2219-2228. [Full Text]
Contreras G, Pardo C, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-98. [Full text]
Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N E J Med 326:1373-79,1992. [Abstract]
Petri M, Jones RJ, Brodsky RA: High –dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis & Rheum 48:166-173,2003.[Full Text]
Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis & Rheum 46; 2673-77, 2002. [Full text]
Looney RJ, Anolik J, Sanz I: B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 16:180-185,2004.[Abstract]
Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down –regulation of the T cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005; 52: 501-13. [Full Text]
Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide –resistant proliferative lupus nephritis. Arthritis Rheum 2007,56:1263-72.[Full Text]
Vigna perez M, et al. Clinical and Immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy. A pilot study. Arthritis Res Ther 8,3R83,2006.[Abstract]
Catapano F, Jones R, Chaudhry A et al. Remission, relapse, and re treatment of 26 SLE patients with rituximab. Lupus 2008, 17: 447-9.
Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis : New insights in to pathogenesis and targeted therapies. Kidney International 2008; 73: 261-68.[Abstract]
Rituxan warning. FDA Consum. 2007;41:3.
Calabrese LH, Molloy ES, Huang D et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28.[Full text]
Alarcon –Segovia d, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo –controlled study. Arthritis Rheum 48:442-54,2003.
Cardiel MH, for the LJP 394-90-09 Study Investigators Group: Randomized, placebo, controlled, double blind phase III clinical trial for the evaluation of LJP 394 in the treatment of patients with SLE who are at risk for renal falre. Ann Rheum Dis 62;81,2003. [Full Text]
Kalunian KC, Davis JC, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti CD154. Arthritis Rehum 46:3251-58,2002.[Full text]
Boumpas DT, Furie R, Manzi S et al. A short course anti CD40 ligand antibody improves serologic activity and decreases hematuria in patients with proliferative lupus nephritis. Arthritis Rheum 48:719-27,2003. [Full text]
Hu W, Liu Z, Shen S, et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J 116: 1827-30,2003. [Full Text]
Moroni G, Maccario M; banfi G et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 31. 681-86,1998.[Abstract]
Mok CC, Ying KY, Lau CS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine : An open label trial. Am J Kidney Dis 43:269-76,2004.[Abstract]
Karim MY, Pisone CM, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44(10):1317-21,2005.[Abstract]
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2009 Universidad Nacional de Córdoba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Se permite la generación de obras derivadas siempre que no se haga con fines comerciales. Tampoco se puede utilizar la obra original con fines comerciales.
Cómo citar
